

**REMARKS**

Claims 1-19, and 21-27 are pending. The Applicant herein respectfully requests further examination of the application and reconsideration of the claims, in view of the amendments and remarks presented herein.

The Applicant respectfully thank the Examiner for acknowledging the patentability of the subject matter of claims 1-17. The Applicants herein specifically amend the scope of claims 18 and 25, without prejudice, to align the scope of the remainder of the pending claims (18-27) in accord with what the Examiner has indicated as allowable subject matter, to expedite the prosecution of this case.<sup>1</sup> Claims 20 and 28-29 are cancelled to avoid redundancy.

Since the particular limitation that the Examiner has indicated confers patentability to the subject matter of the remaining claims, i.e., “wherein at least one other anticancer agent is selected from the group consisting of a steroidal antiandrogen, a non-steroidal antiandrogen, an estrogen, diethylstilbestrol, a conjugated estrogen, a selective estrogen receptor modulator (SERM), a taxane, and a LHRH analog”, is now a required feature in independent claims 18 and 25, the Applicants respectfully submit that all claims now pending define subject matter the Examiner has indicated is allowable.

The Applicants respectfully request the Examiner withdraw the objections to the format of the claims and the rejections under 35 USC §103 in view of the amendments presented herein.


For the foregoing reasons, the Applicant submits that Claims 1-19 and 21-27 are in condition for allowance. Early action toward this end is courteously solicited.

---

<sup>1</sup> “Claims 20-24 are objected to as depending from a rejected claim, but are otherwise in condition for allowance.” Paper of November 17, 2004, at page 5, lines 2-3.

The Commissioner is authorized to charge any deficiency or credit any overpayment to  
Deposit Account No. 50-1943.

Respectfully submitted,



---

Patrick M. Higgins  
Reg. No. 39,709  
Attorney for Applicants

DATE: February 9, 2005

FOX ROTHSCHILD LLP, 997 Lenox Drive, Building 3, Lawrenceville, NJ 08648-2311  
(609) 896-7654 (voice)